CD8A and ovarian carcinoma: Because humoral response to NY-ESO-1 is tightly associated with specific CD8+ and CD4+ T-cell responses against the antigen [40, 41] and is a frequently observed antigen in ovarian cancers [28, 42], we evaluated NY-ESO-1 serology as a surrogate for the presence of T cell responses.